News

2017 2016 2015 2014 2013 2012

7 September 2017	Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®) Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium Read more
21 August 2017	PDMR Dealing LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17,… Read more
8 August 2017	Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update Completed US IPO Read more
2 August 2017	Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that it will… Read more
1 August 2017	Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders… Read more
26 July 2017	Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that the first… Read more
27 June 2017	Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today regulatory appr… Read more
22 June 2017	Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces the appointment… Read more
6 June 2017	Holding(s) in Company TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) Read more
6 June 2017	Holding(s) in Company Read more

1 2 3 4 5 7

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

Download

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Download

Verona Pharma plc

Site map